Table 1.

Use of Antidiabetic Medication(s) in the 4 months before Pregnancy and During the Second or Third Trimester of Pregnancy for 437,950 Pregnancies Resulting in a Live Birth, By Maternal Age Category and Drug Class, 2001–2007

	Maternal Age at Delivery (Years)						Total
	12–24 Years		25–39 Years		40–50 Years		All Women 12–50 Years
Deliveries	n=77,636	%	n=341,020	%	n=19,294	%	N=437,950	%
Any antidiabetic drug during the prepregnancy period*	375	0.48	4610	1.35	314	1.63	5299	1.21
By drug class
Insulin	200	0.26	1153	0.34	98	0.51	1451	0.33
Thiazolidenediones	8	0.01	111	0.03	12	0.06	131	0.03
Biguanide (Metformin)	177	0.23	3319	0.97	183	0.95	3679	0.84
Sulfonylureas	30	0.04	524	0.15	73	0.38	627	0.14
Alpha glucosidase inhibitors	0	--	5	0.00	1	0.01	6	0.00
Meglitinide analogs	0	--	1	0.00	0	--	1	0.00
GLP-1 receptor agonists	0	--	1	0.00	0	--	1	0.00
Combination products†	0	--	4	0.00	0	--	4	0.00
Any antidiabetic drug during second or third trimester	869	1.12	11942	3.50	1376	7.13	14187	3.24
By drug class
Insulin	704	0.91	8989	2.64	1027	5.32	10720	2.45
Thiazolidenediones	0	0.00	6	0.00	2	0.01	8	0.00
Biguanide (Metformin)	23	0.03	540	0.16	45	0.23	608	0.14
Sulfonylureas‡	171	0.22	3085	0.90	388	2.01	3644	0.83
Alpha glucosidase inhibitors	0	--	2	0.00	0	--	2	0.00
Combination products†	1	0.00	2	0.00	0	--	3	0.00

GLP-1, glucagon-like peptide-1.

^*Prepregnancy = 120 days prior to pregnancy.

^†Medications in the combination drugs were disaggregated and included in the individual drug classes. For example, a woman on Glyburide-Metformin is counted in the metformin and sulfonylureas categories.

^‡99% of women who were dispensed a sulfonylurea during pregnancy were dispensed glyburide

DPP-4 and Amyline Analogs were not used prepregnancy or during the second or third trimester of pregnancy.

GLP-1 receptor agonists and meglitinide analogs were not used during the second or third trimester of pregnancy.